Monoamine Oxidase a Polymorphism, Gender, and Smoking as Predictors for Treatment Respose in Olanzapine-treated patients with Schizophrenia

MAOA基因型、性別及抽菸為精神分裂症病人在Olanzapine治療反應之預測因子

10.29478/TJP.201012.0005

鍾廷聖(Ting-Sheng Chung)；龍佛衛(For-Wey Lung)；曾冬勝(Dong-Sheng Tzeng)

MAOA polymorphism ； treatment response ； olanzapine ； schizophrenia

台灣精神醫學

24卷4期（2010 / 12 / 01）

291 - 300

英文

Objective: The aim of this study was to explore the treatment effect of olanzapine on the polymorphisms of monoamine oxidase A (MAOA) in schizophrenia. Method: During a 3-month period, 60 patients with schizophrenia were administered olanzapine. Treatment response was assessed by checking for improvement in symptoms as measured on the Positive and Negative Syndrome Scale (PANSS). Results: The short form of MAOA demonstrated a better drug response in the dimension of aggression. Female patients had a better response to olanzapine. Patients who did not smoke had a better response to olanzapine in the dimension of aggression. Conclusion: The results of this study suggest that polymorphisms of MAOA, gender, and cigarette smoking may be three useful response predictors in schizophrenic patients who were treated with olanzapine.

1. Arndt, S.,Andreasen, N.C.,Flaum, M,Miller, D.,Nopoulos, P.(1995).A longitudinal study of symptom dimensions in schizophrenia: prediction and patterns of change.Arch Gen Psychiatry,52,352-360.
2. Bach, A.W.,Lan, N.C.,Johnson, D.L.(1988).cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties.Proc Natl Acad Sci U S A,85,4934-4938.
3. Bigos, K.L.,Pollock, B.G.,Coley, K.C.(2008).Sex, race, and smoking impact olanzapine exposure.J Clin Pharmacol,48,157-165.
4. Blackwell, B.(1979).Treatment adherence: a contemporary overview.Psychosomatics,20,27-35.
5. Breier, A.,Schreiber, J.L.,Dyer, J.,Pickar, D.(1991).National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome.Arch Gen Psychiatry,48,239-246.
6. Brunner, H.G.,Nelen, M.,Breakefield, X.O.,Ropers, H.H.,van Oost, B.A.(1993).Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A.Science,262,578-580.
7. Buchanan, R.W.,Ball, M.P.,Weiner, E.(2005).Olanzapine treatment of residual positive and negative symptoms.Am J Psychiatry,162,124-129.
8. Bymaster, F.P.,Calligaro, D.O.,Falcone, J.F.(1996).Radioreceptor binding profile of the atypical antipsychotic olanzapine.Neuropsychopharmacology,14,87-96.
9. Callaghan, J.T.,Bergstrom, R.F.,Ptak, L.R.,Beasley, C.M.(1999).Olanzapine. Pharmacokinetic and pharmacodynamic profile.Clin Pharmacokinet,37,177-193.
10. Carrillo, J.A.,Herraiz, A.G.,Ramos, S.I.,Gervasini, G.,Vizcaino, S.,Benitez, J.(2003).Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.J Clin Psychopharmacol,23,119-127.
11. Cases, O.,Seif, I.,Grimsby, J.(1995).Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA.Science,268,1763-1766.
12. Collaborative Working Group on Clinical Trial Evaluations(1998).Assessing the effects of atypical antipsychotics on negative symptoms.J Clin Psychiatry,59(Suppl 12),28-34.
13. Connor, D.F.,Glatt, S.J.,Lopez, I.D.,Jackson, D.,Melloni, R.H., Jr.(2002).Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.J Am Acad Child Adolesc Psychiatry,41,253-261.
14. Coodin, S.,Staley, D.,Cortens, B.,Desrochers, R.,McLandress, S.(2004).Patient factors associated with missed appointments in persons with schizophrenia.Can J Psychiatry,49,145-148.
15. Cramer, J.A.,Rosenheck, R.(1998).Compliance with medication regimens for mental and physical disorders.Psychiatr Serv,49,196-201.
16. de Leon, J.,Becona, E.,Gurpegui, M.,Gonzalez-Pinto, A.,Diaz, F.J.(2002).The association between high nicotine dependence and severe mental illness may be consistent across countries.J Clin Psychiatry,63,812-816.
17. Deckert, J.,Catalano, M.,Syagailo, Y.V.(1999).Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder.Hum Mol Genet,8,621-624.
18. DeLisi, L.E.,Neckers, L.M.,Staub, R.A.,Zalcman, S.J.,Wyatt, R.J.(1980).Lymphocyte monoamine oxidase activity and chronic schizophrenia.Psychiatry Res,2,179-186.
19. Desai, H.D.,Seabolt, J.,Jann, M.W.(2001).Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.CNS Drugs,15,469-494.
20. Goldstein, J.M.,Cohen, L.S.,Horton, N.J.(2002).Sex differences in clinical response to olanzapine compared with haloperidol.Psychiatry Res,110,27-37.
21. Goldstein, J.M.,Seidman, L.J.,Horton, N.J.(2001).Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging.Cereb Cortex,11,490-497.
22. Haro, J.M.,Edgell, E.T.,Novick, D.(2005).Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.Acta Psychiatr Scand,111,220-231.
23. Javitt, D.C.(2004).Glutamate as a therapeutic target in psychiatric disorders.Mol Psychiatry,9,979-997.
24. Kay, S.R.,Figzbein, A.,Opler, L.A.(1987).The postive and negative syndrome scale (PANSS) for schizophrenia.Schizophr Bull,13,261-276.
25. Kelly, D.L.,Conley, R.R.,Tamminga, C.A.(1999).Differential olanzapine plasma concentrations by sex in a fixeddose study.Schizophr Res,40,101-104.
26. Laval, S.H.,Dann, J.C.,Butler, R.J.(1998).Evidence for linkage to psychosis and cerebral asymmetry (relative hand skill) on the X chromosome.Am J Med Genet,81,420-427.
27. Levy, E.R.,Powell, J.F.,Buckle, V.J.,Hsu, Y.P.,Breakefield, X.O.,Craig, I.W.(1989).Localization of human monoamine oxidase-A gene to Xp11.23-11.4 by in situ hybridization: implications for Norrie disease.Genomics,5,368-370.
28. Lieberman, J.A.,Stroup, T.S.,McEvoy, J.P.(2005).Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med,353,1209-1223.
29. Mann, J.J.,Malone, K.M.(1997).Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients.Biol Psychiatry,41,162-171.
30. Meltzer, H.Y.,Duncavage, M.B.,Jackman, H.,Arora, R.C.,Tricou, B.J.,Young, M.(1982).Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients.Am J Psychiatry,139,1242-1248.
31. Murphy, D.L.,Wyatt, R.J.(1972).Reduced monoamine oxidase activity in blood platelets from schizophrenic pa-tients.Nature,238,225-226.
32. Naber, D.,Riedel, M.,Klimke, A.(2005).Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.Acta Psychiatr Scand,111,106-115.
33. Owen, F.,Bourne, R.C.,Crow, T.J.,Fadhli, A.A.,Johnstone, E.C.(1981).Platelet monoamine oxidase activity in acute schizophrenia: relationship to symptomatology and neuroleptic medication.Br J Psychiatry,139,16-22.
34. Perry, P.J.,Lund, B.C.,Sanger, T.,Beasley, C.(2001).Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.J Clin Psychopharmacol,21,14-20.
35. Pollock, B.G.,Wylie, M.,Stack, J.A.(1999).Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women.J Clin Pharmacol,39,936-940.
36. Sabol, S.Z.,Hu, S.,Hamer, D.(1998).A functional: Polymorphism in the monoamine oxidase A gene promoter.Hum Genet,103,273-279.
37. Skogh, E.,Reis, M.,Dahl, M.L.,Lundmark, J.,Bengtsson, F.(2002).Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.Ther Drug Monit,24,518-526.
38. Tollefson, G.D.,Sanger, T.M.(1997).Negative symptoms: a path analytic approach to a double-blind, placeboand haloperidol-controlled zapine.Am J Psychiatry,154,466-474.
39. Weiss, U.,Marksteiner, J.,Kemmler, G.,Saria, A.,Aichhorn, W.(2005).Effects of age and sex on olanzapine plasma concentrations.J Clin Psychopharmacol,25,570-574.
40. Wyatt, R.J.,Potkin, S.G.,Murphy, D.L.(1979).Platelet monoamine oxidase activity in schizophrenia: a review of the data.Am J Psychiatry,136,377-385.
41. Yonkers, K.A.,Kando, J.C.,Cole, J.O.,Blumenthal, S.(1992).Gender differences in pharmacokinetics and pharma-codynamics of psychotropic medication.Am J Psychiatry,149,587-595.
42. Zeger, S.L.,Liang, K.Y.(1986).Longitudinal data analysis for discrete and continuous outcomes.Biometrics,42,121-130.